During the past 30 years the growth period of broilers decreased from 65 days to 35 days. The shortened growth period has resulted in the broiler not having enough time to develop an optimal immune response to traditional vaccines. New vaccine development is focused on day-old or even in-ovo administration, for an adequate immune response. These innovative vaccine's success depends on accurate application. Ceva's development of Hatchery vaccination equipment, as well as technical backup, has found great favour in the market.
The WORLD LEADER in VECTOR and IMMUNE COMPLEX vaccine technology. Since the early nineteen’s, both technologies of Immune Complex and Vector vaccines were known to the scientific community. Few companies in the world have made the effort and the bet to work on these solutions in order to built the bridge between a concept and a real product in the customer’s hand.
Immune Complex vaccine against Infectious Bursal Disease :
Immune complex vaccines consist of IBDVspecific antibodies mixed with a live attenuated IBDV vaccine strain (Winterfield 2512).
The concept aims at avoiding the interference between the maternally derived antibodies (MDA) present in the chicken at hatch and the vaccine virus.
To date, the only disease in which this vaccination concept has found an application is the IBD – the global leader in this category is a Ceva vaccine with more than 3,5 billion vaccinated birds in 2009 and expectation of 5 billions birds in 2010 : Cevac ® Transmune IBD.
allows a durable protection against the disease of Marek and the disease of Newcastle dice one day of old.
VECTORMUNE® is The broadest range of disease protection in a vector vaccine line.
Vector vaccine technology provides advanced disease protection.
The day-old vaccination of chicks is critical to achieve good priming and build a strong basis for the field life and possible revaccination against Newcastle Disease and Infectious Bronchitis.
However, it can induce detrimental post vaccination reaction in the young bird. To overcome this problem, Ceva developed a unique vaccine combination of PHY.LMV.42, apathogenic enterotropic strain of Newcastle Disease virus and the Massachusetts H120 strain of Infectious Bronchitis virus, that allows a safe and efficacious spray application at day-old in the hatchery.
CEVAC® BROILER ND K
offers the best protection in the face of high viral challenge.
The combination of CEVAC® BROILER ND K injected at one day old, with an attenuated live vaccine, produces protection and antibody levels that are significantly higher than those reached from the use of each vaccine individually. This combined vaccination is especially suitable for epidemiological situations where the risks of infection are high.
Full range of Marek vaccines
CEVAC MD HVT : a live virus vaccine containing serotype 3 (HVT) Marek’s disease virus. This Marek’s disease vaccine is presented in a frozen cell associated form.
CEVAC MD RISPENS : is a live virus vaccine containing serotype 1 (Rispens) Marek’s disease virus. This Marek’s disease vaccine is presented in a frozen cell associated form.
CEVAC MD HVT & RISPENS : a live bivalent virus vaccine containing serotypes 1 and 3 (Rispens and HVT) Marek’s disease viruses. This Marek’s disease vaccine is presented in a frozen cell associated form.
VECTORMUNE HVT NDV contains a genetically engineered Marek’s disease virus of serotype 3 (turkey Herpesvirus or HVT) expressing a key antigen of Newcastle disease virus.